Advanced analytics are reshaping how CAR-T therapies move from concept to clinic, challenging long-held assumptions about speed, scale, and quality. However, manufacturers still face trade-offs between rapid expansion, cell fitness, and cost efficiency.
In this episode of Shaping Science, Dr. Pierre Springuel, a postdoctoral researcher at UCL, explores how integrated bioanalytics overcomes key manufacturing barriers. He highlights how smarter, data-driven decisions can optimize both process performance and therapeutic outcomes.
Watch this episode to explore:
- How real-time and high-throughput analytics accelerate CAR-T manufacturing without compromising quality
- Methods to balance expansion speed with cell fitness, potency, and phenotype
- Strategies to reduce waste, improve yield, and lower cost per batch
- Live-Cell Imaging and Analysis—Real-time, Quantitative, and Inside Your Incubator
- Truly Fast. Simply Effortless. High-Throughput Screening (HTS) by Cytometry
- Multi-Parallel Bioreactors for Scalable and Efficient Cell Line Selection and Process Development
- Article—Putting CAR-T Therapy on the Fast Track
- Whitepaper—Phenotypic and Functional Characterization of CAR-T Cells With Advanced Flow Cytometry and Live-Cell Analysis
